Rein Therapeutics (NASDAQ:RNTX) Insider Purchases $25,000.00 in Stock

Rein Therapeutics Inc. (NASDAQ:RNTX) insider James Brian Windsor bought 25,000 shares of the company’s stock in a transaction dated Thursday, April 30th. The stock was bought at an average cost of $1.00 per share, with a total value of $25,000.00. Following the completion of the transaction, the insider owned 27,046 shares in the company, valued at approximately $27,046. This trade represents a 1,221.90% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Rein Therapeutics Stock Down 2.6%

NASDAQ RNTX opened at $1.12 on Wednesday. Rein Therapeutics Inc. has a twelve month low of $1.00 and a twelve month high of $2.40. The firm has a market capitalization of $31.40 million, a PE ratio of -0.57 and a beta of 1.42. The stock’s 50 day moving average is $1.38 and its 200 day moving average is $1.34.

Institutional Trading of Rein Therapeutics

Several institutional investors have recently made changes to their positions in the business. Chicago Partners Investment Group LLC grew its holdings in Rein Therapeutics by 32.2% during the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock valued at $53,000 after buying an additional 10,000 shares in the last quarter. Gagnon Securities LLC raised its holdings in shares of Rein Therapeutics by 5.0% during the 4th quarter. Gagnon Securities LLC now owns 240,220 shares of the company’s stock worth $279,000 after acquiring an additional 11,528 shares in the last quarter. Susquehanna International Group LLP bought a new position in shares of Rein Therapeutics during the 3rd quarter valued at approximately $35,000. HRT Financial LP bought a new position in shares of Rein Therapeutics during the 4th quarter valued at approximately $38,000. Finally, Geode Capital Management LLC grew its holdings in shares of Rein Therapeutics by 15.1% in the fourth quarter. Geode Capital Management LLC now owns 284,555 shares of the company’s stock valued at $330,000 after purchasing an additional 37,244 shares in the last quarter. Hedge funds and other institutional investors own 90.89% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on RNTX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rein Therapeutics in a report on Thursday, January 22nd. downgraded shares of Rein Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. Finally, Citigroup lowered shares of Rein Therapeutics to a “hold” rating in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.00.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.